Brodalumab in the Treatment of Plaque Psoriasis Localized in Difficult-to-Treat Areas: a Narrative Review
Keywords:
brodalumab, psoriasis, pustular psoriasis, scalp, genitals, foldsAbstract
Introduction: Psoriasis is a common chronic, immune-mediated, inflammatory skin disease that in certain localization results difficult to treat. Psoriatic lesions in difficult-to-treat areas might be hardly managed as no standardized therapeutic approach and the application of topical treatments might have marred limitations. Systemic agents, including biologic therapies, have been proven effective in treating this subgroup of patients. In particular, current evidence has shown beneficial effects with the use of brodalumab, a fully human IgG2 monoclonal antibody antagonizing the IL-17 receptor A subunit (IL-17RA).
Objectives: The aim of this narrative review was to collect published data about efficacy and safety of brodalumab in the treatment of psoriasis occurring in difficult-to-treat areas.
Methods: Data on brodalumab effectiveness and safety deriving from both trials and real-world setting that had been published in the last 15 years were collected for this review, together with clinical findings issued during international meetings.
Results: In phase 3 trials, brodalumab demonstrated to be effective in promoting a rapid response in scalp psoriasis as well as in generalized pustular psoriasis and erythrodermic psoriasis. Nail psoriasis demonstrated marked clinical improvement after treatment with brodalumab. Amelioration of palmoplantar psoriasis was also described in brodalumab-treated patients. Various retrospective real-world studies reported a complete clearance of psoriatic lesions in difficult-to-treat areas, including genitalia, through short-term brodalumab treatment.
Conclusions: Brodalumab, combining rapid and sustained efficacy with a favorable safety profile, may be a valid therapeutic option for severe variants of psoriasis as well as for psoriasis localized in difficult-to-treat areas.
References
Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker JNWN. Psoriasis. Lancet. 2021;397(10281):1301-1315. DOI: 10.1016/S0140-6736(20)32549-6. PMID: 33812489.
Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377-385. DOI: 10.1038/jid.2012.339. PMID: 23014338.
Lewis-Beck C, Abouzaid S, Xie L, Baser O, Kim E. Analysis of the relationship between psoriasis symptom severity and quality of life, work productivity, and activity impairment among patients with moderate-to-severe psoriasis using structural equation modeling. Patient Prefer Adherence. 2013;7:199-205. DOI: 10.2147/PPA.S39887. PMID: 23508007. PMCID: PMC3597339.
Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323(19):1945-1960. DOI : 10.1001/jama.2020.4006. PMID: 32427307.
Wozel G. Psoriasis treatment in difficult locations: scalp, nails, and intertriginous areas. Clin Dermatol. 2008;26(5):448-459. DOI: 10.1016/j.clindermatol.2007.10.026. PMID: 18755363.
Handa S. Newer trends in the management of psoriasis at difficult to treat locations: scalp, palmoplantar disease and nails. Indian J Dermatol Venereol Leprol. 2010;76(6):634-644. DOI: 10.4103/0378-6323.72455. PMID: 21079306.
Chan CS, Van Voorhees AS, Lebwohl MG, et al. Treatment of severe scalp psoriasis: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;60(6):962-971. DOI: 10.1016/j.jaad.2008.11.890. PMID: 19375191.
van de Kerkhof PC, Franssen ME. Psoriasis of the scalp. Diagnosis and management. Am J Clin Dermatol. 2001;2(3):159-165. DOI: 10.2165/00128071-200102030-00005. PMID: 11705093.
Zampieron A, Buja A, Fusco M, et al. Quality of life in patients with scalp psoriasis. G Ital Dermatol Venereol. 2015;150(3):309-316. PMID: 25236315.
Nicolescu AC, Ionescu MA, Constantin MM, et al. Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness. Life (Basel). 2022;12(12):2050. DOI: 10.3390/life12122050. PMID: 36556415. PMCID: PMC9785802.
Bardazzi F, Starace M, Bruni F, Magnano M, Piraccini BM, Alessandrini A. Nail Psoriasis: An Updated Review and Expert Opinion on Available Treatments, Including Biologics. Acta Derm Venereol. 2019;99(6):516-523. DOI: 10.2340/00015555-3098. PMID: 30521057.
Stewart CR, Algu L, Kamran R, et al. The Impact of Nail Psoriasis and Treatment on Quality of Life: A Systematic Review. Skin Appendage Disord. 2021;7(2):83-89. DOI: 10.1159/000512688. PMID: 33796553. PMCID: PMC7991285.
Chung J, Callis Duffin K, Takeshita J, et al. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2014;71(4):623-632. DOI: 10.1016/j.jaad.2014.04.063. PMID: 24894455. PMCID: PMC4165651.
European Medicines Agency. Kyntheum (brodalumab) 210 mg solution for injection in pre-filled syringe: Summary of Product Characteristics. Date of first authorisation:17 July 2017 Availabre from from:https://www.ema.europa.eu/en/documents/product-information/kyntheum-epar-product-information_en.pdf. Accessed on..
LeoPharma A/S. SILIQTM (brodalumab) injection, for subcutaneous use. Initial U.S. approval: 2017.Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf
Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273-286. DOI: 10.1111/bjd.14493. PMID: 26914406.
Fargnoli MC, Bardazzi F, Bianchi L, et al. Brodalumab for the Treatment of Moderate-to-Severe Psoriasis: An Expert Delphi Consensus Statement. J Clin Med. 2023;12(10):3545. DOI: 10.3390/jcm12103545. PMID: 37240650. PMCID: PMC10219103.
McMichael A, Desai SR, Qureshi A, Rastogi S, Alexis AF. Efficacy and Safety of Brodalumab in Patients with Moderate-to-Severe Plaque Psoriasis and Skin of Color: Results from the Pooled AMAGINE-2/-3 Randomized Trials. Am J Clin Dermatol. 2019;20(2):267-276. DOI: 10.1007/s40257-018-0408-z. PMID: 30471012.
Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379-390. DOI: 10.1007/s12016-018-8702-3. PMID: 30109481. PMCID: PMC6244934.
Di Cesare A, Di Meglio P, Nestle FO. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J Invest Dermatol. 2009;129(6):1339-1350. DOI: 10.1038/jid.2009.59. PMID: 19322214.
Martin DA, Towne JE, Kricorian G, et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol. 2013;133(1):17-26. DOI: 10.1038/jid.2012.194. PMID: 22673731; PMCID: PMC3568997.
Johansen C, Usher PA, Kjellerup RB, Lundsgaard D, Iversen L, Kragballe K. Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. Br J Dermatol. 2009;160(2):319-324. DOI: 10.1111/j.1365-2133.2008.08902.x. PMID: 19016708.
Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003;14(2):155-174. DOI: 10.1016/s1359-6101(03)00002-9. PMID: 12651226.
Chiricozzi A, Suárez-Fariñas M, Fuentes-Duculan J, et al. Increased expression of interleukin-17 pathway genes in nonlesional skin of moderate-to-severe psoriasis vulgaris. Br J Dermatol. 2016;174(1):136-145. DOI: 10.1111/bjd.14034. PMID: 26189551. PMCID: PMC4720589.
Krueger JG, Fretzin S, Suárez-Fariñas M, et al. IL-17A is essential for cell activation and inflammatory gene circuits in subjects with psoriasis. J Allergy Clin Immunol. 2012;130(1):145-154.e9. DOI: 10.1016/j.jaci.2012.04.024. PMID: 22677045. PMCID: PMC3470466.
Su Y, Huang J, Zhao X, et al. Interleukin-17 receptor D constitutes an alternative receptor for interleukin-17A important in psoriasis-like skin inflammation. Sci Immunol. 2019;4(36):eaau9657. DOI: 10.1126/sciimmunol.aau9657. PMID: 31175175.
Facheris P, Valenti M, Pavia G, et al. Brodalumab: A new way to inhibit IL-17 in psoriasis. Dermatol Ther. 2020;33(3):e13403. DOI: 10.1111/dth.13403. PMID: 32285564.
Kirkham BW, Kavanaugh A, Reich K. Interleukin-17A: a unique pathway in immune-mediated diseases: psoriasis, psoriatic arthritis and rheumatoid arthritis. Immunology. 2014;141(2):133-142. DOI: 10.1111/imm.12142. PMID: 23819583. PMCID: PMC3904234.
Chiricozzi A, Romanelli P, Volpe E, Borsellino G, Romanelli M. Scanning the Immunopathogenesis of Psoriasis. Int J Mol Sci. 2018;19(1):179. DOI: 10.3390/ijms19010179. PMID: 29316717. PMCID: PMC5796128.
Chiricozzi A, Nograles KE, Johnson-Huang LM, et al. IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model. PLoS One. 2014;9(2):e90284. DOI: 10.1371/journal.pone.0090284. PMID: 24587313. PMCID: PMC3938679.
Tollenaere MAX, Hebsgaard J, Ewald DA, et al. Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways. Br J Dermatol. 2021;185(3):585-594. DOI: 10.1111/bjd.20090. PMID: 33792895. PMCID: PMC8453543.
Ramirez-Carrozzi V, Sambandam A, Luis E, et al. IL-17C regulates the innate immune function of epithelial cells in an autocrine manner. Nat Immunol. 2011;12(12):1159-1166. DOI: 10.1038/ni.2156. PMID: 21993848.
Krueger JG, Brunner PM. Interleukin-17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities. Exp Dermatol. 2018;27(2):115-123. DOI: 10.1111/exd.13467. PMID: 29152791.
Lauffer F, Jargosch M, Baghin V, et al. IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema. J Eur Acad Dermatol Venereol. 2020;34(4):800-809. DOI: 10.1111/jdv.16126. PMID: 31793105.
doi: 10.4049/jimmunol.1201505. Johnston A, Fritz Y, Dawes SM, et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol. 2013;190(5):2252-2262. DOI: 10.4049/jimmunol.1201505. PMID: 23359500. PMCID: PMC3577967.
Guttman-Yassky E, Krueger JG. IL-17C: A Unique Epithelial Cytokine with Potential for Targeting across the Spectrum of Atopic Dermatitis and Psoriasis. J Invest Dermatol. 2018;138(7):1467-1469. DOI: 10.1016/j.jid.2018.02.037. PMID: 29941097.
Chang SH, Reynolds JM, Pappu BP, Chen G, Martinez GJ, Dong C. Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E. Immunity. 2011;35(4):611-621. DOI: 10.1016/j.immuni.2011.09.010. PMID: 21982598. PMCID: PMC5800502.
Nies JF, Panzer U. IL-17C/IL-17RE: Emergence of a Unique Axis in TH17 Biology. Front Immunol. 2020;11:341. DOI: 10.3389/fimmu.2020.00341. PMID: 32174926. PMCID: PMC7054382.
Merola JF, Qureshi A, Husni ME. Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589. DOI: 10.1111/dth.12589. PMID: 29512290. PMCID: PMC6901032.
Menter A, Bhutani T, Ehst B, Elewski B, Jacobson A. Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis. Dermatol Ther (Heidelb). 2022;12(6):1289-1302. DOI: 10.1007/s13555-022-00746-6. PMID: 35672564. PMCID: PMC9209590.
Rich P, Gooderham M, Bachelez H, et al. Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2). J Am Acad Dermatol. 2016;74(1):134-142. DOI: 10.1016/j.jaad.2015.09.001. PMID: 26549249.
Ten Bergen LL, Petrovic A, Krogh Aarebrot A, Appel S. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol. 2020;92(4):e12946. DOI: 10.1111/sji.12946. PMID: 32697374.
Tomalin LE, Russell CB, Garcet S, et al. Short-term transcriptional response to IL-17 receptor-A antagonism in the treatment of psoriasis. J Allergy Clin Immunol. 2020;145(3):922-932. DOI: 10.1016/j.jaci.2019.10.041. PMID: 31883845.
Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. N Engl J Med. 2014;371(4):326-338. DOI: 10.1056/NEJMoa1314258. PMID: 25007392.
Griffiths CE, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet. 2015;386(9993):541-551. DOI: 10.1016/S0140-6736(15)60125-8. PMID: 26072109.
Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021;397(10273):475-486. DOI: 10.1016/S0140-6736(21)00126-4. Lancet. 2021;397(10280):1182. PMID: 33549192.
Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10273):487-498. DOI: 10.1016/S0140-6736(21)00125-2. PMID: 33549193.
Lebwohl M, Strober B, Menter A, et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015;373(14):1318-1328. DOI: 10.1056/NEJMoa1503824. PMID: 26422722.
Papp KA, Reich K, Paul C, et al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273-286. DOI: 10.1111/bjd.14493. PMID: 26914406.
Gallais Sérézal I, Classon C, Cheuk S, et al. Resident T Cells in Resolved Psoriasis Steer Tissue Responses that Stratify Clinical Outcome. J Invest Dermatol. 2018;138(8):1754-1763. DOI: 10.1016/j.jid.2018.02.030. PMID: 29510191.
.Russell CB, Rand H, Bigler J, et al. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody. J Immunol. 2014;192(8):3828-3836. DOI: 10.4049/jimmunol.1301737. PMID: 24646743.
Elewski B, Rich P, Lain E, Soung J, Lewitt GM, Jacobson A. Efficacy of brodalumab in the treatment of scalp and nail psoriasis: results from three phase 3 trials. J Dermatolog Treat. 2022;33(1):261-265. DOI: 10.1080/09546634.2020.1749546. PMID: 32250714.
Nakagawa H, Niiro H, Ootaki K; Japanese brodalumab study group. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81(1):44-52. DOI: 10.1016/j.jdermsci.2015.10.009. PMID: 26547109.
Gregoriou S, Tsiogka A, Tsimpidakis A, Nicolaidou E, Kontochristopoulos G, Rigopoulos D. Treatment of nail psoriasis with brodalumab: an open-label unblinded study. J Eur Acad Dermatol Venereol. 2021;35(4):e299-e301. DOI: 10.1111/jdv.17055. PMID: 33269501.
Husein-ElAhmed H, Husein-ElAhmed S. Bayesian network meta-analysis of head-to-head trials for complete resolution of nail psoriasis. Clin Exp Dermatol. 2023:llad136. DOI: 10.1093/ced/llad136. PMID: 37052062.
Yukari Okubo Y et al. Efficacy and Safety of Brodalumab, An Anti-Interleukin-17 Receptor A Monoclonal Antibody, in Japanese Patients with Palmoplantar Pustulosis: A 16 Week Results of a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study. Abstract 85. EADV 2022.
Yamasaki K, Nakagawa H, Kubo Y, Ootaki K; Japanese Brodalumab Study Group. Efficacy and safety of brodalumab in patients with generalized pustular psoriasis and psoriatic erythroderma: results from a 52-week, open-label study. Br J Dermatol. 2017;176(3):741-751. DOI: 10.1111/bjd.14702. PMID: 27106510.
Galluzzo M, D'adamio S, Bianchi L, Talamonti M. Brodalumab for the treatment of psoriasis. Expert Rev Clin Immunol. 2016;12(12):1255-1271. DOI: 10.1080/1744666X.2016.1246957. PMID: 27718760.
Pinter A, Bonnekoh B, Hadshiew IM, Zimmer S. Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review. Clin Cosmet Investig Dermatol. 2019;12:509-517. DOI: 10.2147/CCID.S211938. PMID: 31372022. PMCID: PMC6628099.
Politou M, Pompou M, Afroditi KI, Giannoukos A, Nikolaos F. Twenty patients with moderate to severe psoriasis successfully treated with brodalumab after a failed treatment with secukinumab. J Am Acad Dermatol. 2020;83(6 suppl): AB214.
Nakao M, Asano Y, Kamata M, Yoshizaki A, Sato S. Successful treatment of palmoplantar pustular psoriasis with brodalumab. Eur J Dermatol. 2018;28(4):538-539. DOI: 10.1684/ejd.2018.3325. PMID: 30129522.
Pinter A, Wilsmann-Theis D, Peitsch WK, Mössner R. Interleukin-17 receptor A blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases. J Dermatol. 2019;46(5):426-430. DOI: 10.1111/1346-8138.14815. PMID: 30786053.
Published
Issue
Section
License
Copyright (c) 2023 Giulia Coscarella
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
